Copaiba oil enhances in vitro/in vivo cutaneous permeability and in vivo anti-inflammatory effect of celecoxib
© 2018 Royal Pharmaceutical Society..
OBJECTIVES: The aim of this article was to use copaiba oil (C.O) to improve skin permeability and topical anti-inflammatory activity of celecoxib (Cxb).
METHODS: Formulations containing C.O (1-50%) were associated with Cxb (2%). In vitro skin permeability studies were conducted using porcine ear skin. Histological analysis of the hairless mice skin samples after application of formulations was achieved with the routine haematoxylin/eosin technique. The anti-inflammatory activity was assessed using the AA-induced ear oedema mice model.
KEY FINDINGS: The formulation containing 25% C.O promoted the highest levels of in vitro Cxb permeation through pig ear skin, retention in the stratum corneum (SC) and epidermis/dermis of pig ear skin in vitro (~5-fold) and hairless mice skin in vivo (~2.0-fold), as compared with the control formulation. At 25%, C.O caused SC disorganization and increased cell infiltration and induced angiogenesis without clear signs of skin irritation. The formulation added to 25% C.O as adjuvant inhibited ear oedema and protein extravasation by 77.51 and 89.7%, respectively, and that it was, respectively, 2.0- and 3.4-fold more efficient than the commercial diethylammonium diclofenac cream gel to suppress these inflammatory parameters.
CONCLUSIONS: 25% C.O is a potential penetration enhancer for lipophilic drugs like Cxb that can improve cutaneous drug penetration and its anti-inflammatory activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
The Journal of pharmacy and pharmacology - 70(2018), 7 vom: 30. Juli, Seite 964-975 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quiñones, Oliesia Gonzalez [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.10.2018 Date Revised 01.01.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jphp.12906 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM282500707 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282500707 | ||
| 003 | DE-627 | ||
| 005 | 20231225034048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jphp.12906 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0941.xml |
| 035 | |a (DE-627)NLM282500707 | ||
| 035 | |a (NLM)29600536 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quiñones, Oliesia Gonzalez |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Copaiba oil enhances in vitro/in vivo cutaneous permeability and in vivo anti-inflammatory effect of celecoxib |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2018 | ||
| 500 | |a Date Revised 01.01.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 Royal Pharmaceutical Society. | ||
| 520 | |a OBJECTIVES: The aim of this article was to use copaiba oil (C.O) to improve skin permeability and topical anti-inflammatory activity of celecoxib (Cxb) | ||
| 520 | |a METHODS: Formulations containing C.O (1-50%) were associated with Cxb (2%). In vitro skin permeability studies were conducted using porcine ear skin. Histological analysis of the hairless mice skin samples after application of formulations was achieved with the routine haematoxylin/eosin technique. The anti-inflammatory activity was assessed using the AA-induced ear oedema mice model | ||
| 520 | |a KEY FINDINGS: The formulation containing 25% C.O promoted the highest levels of in vitro Cxb permeation through pig ear skin, retention in the stratum corneum (SC) and epidermis/dermis of pig ear skin in vitro (~5-fold) and hairless mice skin in vivo (~2.0-fold), as compared with the control formulation. At 25%, C.O caused SC disorganization and increased cell infiltration and induced angiogenesis without clear signs of skin irritation. The formulation added to 25% C.O as adjuvant inhibited ear oedema and protein extravasation by 77.51 and 89.7%, respectively, and that it was, respectively, 2.0- and 3.4-fold more efficient than the commercial diethylammonium diclofenac cream gel to suppress these inflammatory parameters | ||
| 520 | |a CONCLUSIONS: 25% C.O is a potential penetration enhancer for lipophilic drugs like Cxb that can improve cutaneous drug penetration and its anti-inflammatory activity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-inflammatory activity | |
| 650 | 4 | |a celecoxib | |
| 650 | 4 | |a copaiba oil | |
| 650 | 4 | |a cutaneous permeability | |
| 650 | 4 | |a topical administration | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Diethylamines |2 NLM | |
| 650 | 7 | |a Oils, Volatile |2 NLM | |
| 650 | 7 | |a Diclofenac |2 NLM | |
| 650 | 7 | |a 144O8QL0L1 |2 NLM | |
| 650 | 7 | |a diclofenac diethylamine |2 NLM | |
| 650 | 7 | |a 6TGQ35Z71K |2 NLM | |
| 650 | 7 | |a Celecoxib |2 NLM | |
| 650 | 7 | |a JCX84Q7J1L |2 NLM | |
| 700 | 1 | |a Hossy, Bryan Hudson |e verfasserin |4 aut | |
| 700 | 1 | |a Padua, Tatiana Almeida |e verfasserin |4 aut | |
| 700 | 1 | |a Miguel, Nádia Campos de Oliveira |e verfasserin |4 aut | |
| 700 | 1 | |a Rosas, Elaine Cruz |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Mônica Freiman de Souza |e verfasserin |4 aut | |
| 700 | 1 | |a Pierre, Maria Bernadete Riemma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of pharmacy and pharmacology |d 1949 |g 70(2018), 7 vom: 30. Juli, Seite 964-975 |w (DE-627)NLM000019046 |x 2042-7158 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2018 |g number:7 |g day:30 |g month:07 |g pages:964-975 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jphp.12906 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2018 |e 7 |b 30 |c 07 |h 964-975 | ||